Semaglutide is a compound belonging to a class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists
promotes optimal cell function and helps eliminate toxins for overall well-being
In clinical trials, Wegovy led to an average weight loss of 14.9% over 68 weeks, compared to 5.4% over 56 weeks with Contrave
Parts of several figures were made using the BioRender programme
Synergistic Integration Together, these four peptides address the complete repair cascade: KPV controls early inflammation, BPC-157 establishes vascular support and cytoprotection, TB-500 mobilizes cells into the site of repair, and GHK-Cu drives extracellular matrix synthesis and longer-term remodeling
8.2 Emerging Therapeutic Opportunities The insights garnered from future research have the potential to revolutionize the use of semaglutide in clinical practice, especially for patients on hormone therapy